Immuno-Oncology Landscape

Let's spread the word about Immunotherapy! Click to share this page with your community.

With an unprecedented number of new investigational agents and companies in immuno-oncology (IO), it has been difficult to track and understand the current IO agents in clinical development and the clinical trials testing these agents. The Clinical Accelerator team presents an unbiased, neutral, scientifically curated, and timely updated analysis based on information collected from numerous trusted and publicly available sources.

We hope to inform the cancer research community through academic publications as it strives for efficiencies and innovation while avoiding duplication. We also present the following interactive dashboards of this landscape of immuno-oncology drug development that explore the field: 

A comparison of global IO pipelines in 2017 and 2018. 3,394 immuno-oncology agents in six main classes were identified in September 2018, an increase of 67% since the previous survey. More details can be found in the Nature Reviews Drug Discovery article.

Please note that all landscape dashboards are integrated with the CRI iAtlas for further exploration of the molecular targets. 

As of today, we have five landscape publications:

Additionally, data from our Immuno-Oncology Landscape has been featured in a review of IO combination trials in breast cancer:

Explore other landscapes of immuno-oncology drug development: 

Data Sources: Cancer Research Institute (CRI) analytics derive from public data sources, including trade news, company press releases, academic publications, FDA announcements,, and conference reports, and proprietary data sources including, but not limited to, GlobalData. The analytical algorithm and visualizations are developed by and therefore sole property of Cancer Research Institute.

Subscribe to our email newsletter to receive the latest updates on our landscape analyses.

*Immunotherapy results may vary from patient to patient.